Dr. Post is Vivace’s Chief Scientific Officer and a member of the board of directors, bringing more than three decades of pharmaceutical experience spanning companies of all sizes. Before joining Vivace in 2016, he served as chief scientific officer of BioMarin, a publicly held biopharmaceutical firm with a focus on rare diseases. He joined BioMarin when the company acquired LEAD Therapeutics, a drug discovery company where he was a co-founder and served as CSO. He was responsible for inception as well as subsequent development of talazoparib until it was sold to Medivation by BioMarin. Positions prior to LEAD included senior vice president of research and development for Onyx Pharmacueticals and vice president of discovery research for Parke-Davis Pharmaceuticals. Dr. Post has been the direct supervisor and mentor for Dr. Y. Shen since 2000.

Dr. Post holds a doctorate in biochemistry from the University of Wisconsin and a B.S. in Chemistry from the University of Michigan.